August 3, 2022

The FDA has approved Juvéderm® Volux™ XC (hyaluronic acid) to improve moderate to severe loss of jawline definition in adults older than 21 years.

  • The product is the newest addition to the Juvéderm line of injectable gels for cosmetic use made by Allergan Juvéderm injectable gels treat wrinkles and lines in cheeks, chin, lips, and undereye hollows.
  • Juvéderm Volux XC is administered via deep injection by a trained healthcare professional. The manufacturer plans to launch healthcare provider training in the fall of 2022, with wider product distribution expected in 2023.
August 18, 2022

U.S. FDA Approves First Cetrotide Generic

Read More
August 17, 2022

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Read More